Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 6/20 | 0.37 |
| ▸ | GSK3A | P49840 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627191 | 0.79 | RAB9A (0.35) | HSD11B1KMT2AMEN1USP2KDM4E | |
| SCHEMBL9044821 | 0.72 | KMT2A (0.39) | KMT2AMEN1MAPTKDM4EALDH1A1 | |
| SCHEMBL9044806 | 0.72 | KMT2A (0.39) | KMT2AMEN1MAPTKDM4EALDH1A1 | |
| SCHEMBL13430583 | 0.71 | — | — | |
| SCHEMBL8055478 | 0.66 | CRBN (0.30) | GSK3B | |
| SCHEMBL5675756 | 0.65 | KMT2A (0.46) | HSD11B1KMT2AMEN1USP2MAPT | |
| SCHEMBL5677692 | 0.64 | CDYL2 (0.46) | KMT2AMEN1USP2MAPTKDM4E | |
| SCHEMBL14939263 | 0.64 | RAB9A (0.57) | HSD11B1KMT2AMEN1USP2MAPT | |
| SCHEMBL31559140 | 0.63 | SMN1; SMN2 (0.37) | KMT2AMEN1MAPTKDM4EALDH1A1 | |
| SCHEMBL11115795 | 0.62 | ALDH1A1 (0.64) | HSD11B1KMT2AMEN1USP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136015-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | SANDOZ AG (CH) | 2012-05-31 | — | — | US | disclosed |
| EP-2419421-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | Sandoz AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010118992-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | SANDOZ AG (CH) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136015-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | EDNRA, EDNRB, TBXA2R | HSD11B1 2547/4885KMT2A 3799/4885MEN1 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.